Metagenomi, Common Stock Stock Today
| MGX Stock | 1.64 0.04 2.38% |
PerformanceVery Weak
| Odds Of DistressQuite High
|
Metagenomi, Common is trading at 1.64 as of the 22nd of March 2025; that is 2.38 percent decrease since the beginning of the trading day. The stock's open price was 1.68. Metagenomi, Common has more than 68 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Moving together with Metagenomi, Stock
Moving against Metagenomi, Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Metagenomi, Stock Highlights
| CEO CoFounder | Brian Thomas |
| Old Names | [MOUNT GIBSON IRON, MAGIX N - Frankfurt Stock Exchang] |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Metagenomi, Common Stock (MGX) is traded on NASDAQ Exchange in USA. It is located in 5959 Horton Street, Emeryville, CA, United States, 94608 and employs 202 people. Metagenomi, Common is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 62.8 M. Metagenomi, Common Stock runs under Biotechnology sector within Health Care industry. The entity has 37.38 M outstanding shares of which 2.57 M shares are now shorted by investors with about 4.79 days to cover.
Metagenomi, Common generates negative cash flow from operations
Check Metagenomi, Common Probability Of Bankruptcy
Ownership AllocationMetagenomi, Common Stock maintains a total of 37.38 Million outstanding shares. Metagenomi, Common Stock holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Metagenomi, Ownership Details
Metagenomi, Common Stock Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Metagenomi, Common market risk premium is the additional return an investor will receive from holding Metagenomi, Common long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.23) | |||
| Jensen Alpha | (1.35) | |||
| Total Risk Alpha | (0.98) | |||
| Treynor Ratio | 32.32 |
Metagenomi, Stock Against Markets
Metagenomi, Common Corporate Management
| Pamela MBA | Chief Officer | Profile | |
| Simon MSc | Chief Relations | Profile | |
| Luis Borges | Chief Officer | Profile | |
| Matthew JD | Compliance Legal | Profile |
Additional Tools for Metagenomi, Stock Analysis
When running Metagenomi, Common's price analysis, check to measure Metagenomi, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Metagenomi, Common is operating at the current time. Most of Metagenomi, Common's value examination focuses on studying past and present price action to predict the probability of Metagenomi, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Metagenomi, Common's price. Additionally, you may evaluate how the addition of Metagenomi, Common to your portfolios can decrease your overall portfolio volatility.